• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • RVU Search
    • NPI Registry Lookup
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • RVU Search
    • NPI Registry Lookup
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Pituitary microadenomas exhibit slow growth and may require less frequent MRI surveillance

byBryant LimandKiera Liblik
March 18, 2023
in Chronic Disease, Endocrinology, Imaging and Intervention, Neurology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In this retrospective cohort study, two-thirds of incidental pituitary microadenomas remained unchanged or decreased in size over a median follow-up of 4.91 years.

2. Smaller (less than or equal to 4mm) and larger (greater than 4mm) pituitary microadenomas were more likely to increase and decrease in size over time, respectively.

Evidence Rating Level: 2 (Good)

Study Rundown: Current guidelines, published in 2011, recommend pituitary magnetic resonance imaging (MRI) after initial pituitary microadenoma diagnosis. Further, it is recommended this be followed by annual or biannual imaging for the next three years. No updated guidelines have been proposed, likely due to the paucity of new evidence in this area. In this retrospective cohort study, patients with pituitary microadenomas identified at the Mass General Brigham, Boston, Massachusetts, between 2003 and 2021 had their imaging analyzed. Microadenoma size resulted in minimal change, with two-thirds of cases having stable or decreased size over time. Tumors with a baseline size of 4mm or less were more likely to increase in size during follow-up. Conversely, those with a baseline tumor size of more than 4mm tended to decrease in size. Less than 2% of the total microadenomas progressed to macroadenomas. In terms of limitations, this study used a retrospective design, and there were large variabilities in MRI study intervals and follow-up durations between patients.

Click to read the study in AIM

In-Depth [retrospective cohort study]: In this retrospective cohort study, patients (n=414) diagnosed with a pituitary microadenoma (tumor size ≤10 mm) from the Mass General Brigham, Boston, Massachusetts, between 2003 and 2021 were included. The patient median follow-up time was 4.91 years (95% Confidence Interval [CI], 3.88 to 5.32 years). In total, 44%, 19%, and 28% of microadenomas remained unchanged, decreased, or increased in size, respectively. A small proportion of microadenomas (1.7%) progressed to macroadenomas (adenomas over 10 mm). A mixed model linear regression analysis was used to estimate the pituitary microadenoma size trajectory over time. For all patients, the estimated slope was 0.016 mm/year (CI, -0.038 to 0.069). For tumors sized 4mm or less, the size tended to increase (estimated slope 0.09 mm/year; CI, 0.020 to 0.161). For tumors over 44mm, the size tended to decrease (estimated slope -0.063 mm/year; CI, -0.141 to 0.015). This study supports revised guidelines recommending increasing the time interval between pituitary MRIs in patients with pituitary microadenomas of limited size.

RELATED REPORTS

Guideline-based lymph node sampling is not associated with increased postoperative complications in lung cancer

Why Pfizer Is Looking East for Its Next Generation of Cancer Drugs

2MM: Pharma Roundup – Pfizer’s $10.5B Innovent oncology partnership, Guselkumab (Tremfya) gains a broader psoriatic arthritis label, Venetoclax (Venclyxto) expands first-line CLL options, and Seladelpar (Livdelzi) advances in primary biliary cholangitis

Image: PD

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: chronic diseaseendocrinologyimagingimaging and interventionincidentalomaneurologyoncologypituitarypituitary adenomapituitary incidentalomapituitary macroadenomapituitary microadenomaPituitary Tumors
Previous Post

Bedaquiline-linezolid regimen noninferior to standard treatment for tuberculosis

Next Post

#VisualAbstract: Sotorasib superior to docetaxel for treatment of KRASG12C-positive non-small-cell lung cancer

RelatedReports

Lessons from real-world implementation of lung cancer screening
Chronic Disease

Guideline-based lymph node sampling is not associated with increased postoperative complications in lung cancer

June 9, 2026
Quick Take: Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial
Oncology

Why Pfizer Is Looking East for Its Next Generation of Cancer Drugs

June 4, 2026
2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]
Pharma

2MM: Pharma Roundup – Pfizer’s $10.5B Innovent oncology partnership, Guselkumab (Tremfya) gains a broader psoriatic arthritis label, Venetoclax (Venclyxto) expands first-line CLL options, and Seladelpar (Livdelzi) advances in primary biliary cholangitis

June 3, 2026
Chronic Disease

Immunosuppression with systemic glucocorticoids close to initiation of immune checkpoint inhibitor is associated with worse survival outcomes

May 25, 2026
Next Post
#VisualAbstract: Sotorasib superior to docetaxel for treatment of KRASG12C-positive non-small-cell lung cancer

#VisualAbstract: Sotorasib superior to docetaxel for treatment of KRASG12C-positive non-small-cell lung cancer

#VisualAbstract: Routine invasive strategy not associated with improved outcomes in older adults with frailty and non-ST segment elevation acute myocardial infarction

Intensive rehabilitation not superior to traditional therapy for arm function after stroke

2 Minute Medicine Rewind March 20, 2023

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Food coloring additives are associated with higher incidence of type 2 diabetes
  • Children conceived through infertility treatments may have similar growth compared to naturally conceived children
  • Ring-augmented one-anastomosis gastric bypass may not improve weight loss compared to conventional one-anastomosis gastric bypass
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • RVU Search
    • NPI Registry Lookup
  • Pharma
  • AI News
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.